Valuation: Halozyme Therapeutics, Inc.

Market Cap 9.9B 8.69B 8.09B 7.44B 13.95B 946B 14.19B 95.96B 37.56B 469B 37.16B 36.36B 1,620B P/E 2026 *
12.5x
P/E 2027 * 9.61x
Enterprise Value 11.22B 9.85B 9.17B 8.43B 15.81B 1,072B 16.08B 109B 42.58B 532B 42.12B 41.21B 1,837B EV / Sales 2026 *
6.35x
EV / Sales 2027 * 5.04x
Free-Float
98.94%
Yield 2026 *
-
Yield 2027 * -
1 day+2.41%
1 week+6.16%
Current month+6.61%
1 month+11.32%
3 months+30.67%
6 months+14.58%
Current year+23.99%
1 week 76.82
Extreme 76.8207
84.44
1 month 73.89
Extreme 73.8901
84.44
Current year 61.32
Extreme 61.325
84.44
1 year 58.53
Extreme 58.53
84.44
3 years 32.83
Extreme 32.83
84.44
5 years 29.85
Extreme 29.85
84.44
10 years 8.18
Extreme 8.18
84.44
Manager TitleAgeSince
Chief Executive Officer 63 2014-01-05
Director of Finance/CFO 61 2013-04-30
Director of Finance/CFO - 2026-06-07
Director TitleAgeSince
Director/Board Member 59 2013-03-27
Director/Board Member 63 2014-01-05
Chairman 61 -
Date Insider Type Main position Quantity % Market Cap.
7/8/26 Fiscal year

Chief Executive Officer

5,769 0.0049%
7/1/26 Free

Chief Financial Officer

168,986 0.1425%
7/1/26 Free

Executive/Senior Manager

56,055 0.0473%
Change 5-day change 1-year change 3-year change Capi.($)
+2.41%+6.16%+44.54%+91.12% 9.66B
+0.81%+4.40%+56.82%+23.96% 323B
+1.56%+2.78%+4.53%-0.59% 8.51B
-2.93%+2.45%-20.66%-2.69% 4.37B
-3.73%-3.89%-9.31%+1.86% 3.75B
-1.81%+1.58%-41.23%+7.12% 3.66B
+1.60%-0.29%+42.86%+56.90% 2.73B
-0.87%-4.54%-7.97%-10.77% 2.11B
-5.16%-6.21%-20.06%+18.69% 1.87B
-0.58%-1.15%-23.40%-21.01% 1.72B
Average -0.86%-0.20%+2.61%+16.46% 36.13B
Weighted average by Cap. +0.71%+4.66%+51.38%+24.26%

Financials

2026 *2027 *
Net sales 1.77B 1.55B 1.44B 1.33B 2.49B 169B 2.53B 17.14B 6.71B 83.75B 6.64B 6.49B 289B 2B 1.76B 1.64B 1.51B 2.82B 192B 2.87B 19.43B 7.61B 94.97B 7.53B 7.36B 328B
Net income 812M 713M 664M 610M 1.14B 77.58B 1.16B 7.87B 3.08B 38.48B 3.05B 2.98B 133B 1.03B 908M 845M 777M 1.46B 98.8B 1.48B 10.03B 3.92B 49B 3.88B 3.8B 169B
Net Debt 1.32B 1.16B 1.08B 994M 1.86B 126B 1.9B 12.82B 5.02B 62.66B 4.96B 4.86B 216B 205M 180M 167M 154M 289M 19.57B 294M 1.99B 777M 9.71B 769M 752M 33.53B
Logo Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
Employees
423
Date Price Change Volume
26-07-28 US$83.45 +2.41% 2,623,590
26-07-27 US$81.48 -0.55% 1,435,892
26-07-24 US$81.93 +1.35% 1,661,209
26-07-23 US$80.84 +3.88% 1,751,413
26-07-22 US$77.82 -0.99% 1,399,919
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
83.44USD
Average target price
86.89USD
Spread / Average Target
+4.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HALO Stock